Navigation Links
BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
Date:9/28/2011

RALEIGH, N.C., Sept. 28, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the preliminary findings of the Company's randomized, placebo-controlled, Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in a mixed opioid naive and opioid experienced population.  The primary endpoint of the study, overall pain intensity difference between BEMA Buprenorphine and placebo, was not achieved; however, BDSI believes that the totality of the study results favors BEMA Buprenorphine, including a near statistically significant difference between BEMA Buprenorphine and placebo in the opioid experienced group of patients in the trial (p=0.067).  In addition, when eliminating the group of patients that did not titrate beyond the starting dose, a statistically significant difference between BEMA Buprenorphine and placebo (p=0.025) was identified.  With the knowledge gained from this study, the Company plans to initiate a second efficacy study in the near future that will take approximately nine months to complete.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"We witnessed a high placebo response in the opioid naive segment of our patient population, particularly at our starting dose, which accounted for the overall lack of efficacy that was observed in this trial," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "This group of patients, who are not accustomed to taking opioids and prone to higher placebo effects, accounted for nearly two-thirds of the total study population.  When we eliminate the BEMA Buprenorphine starting dose from the analysis, where the greatest placebo response occurred, particularly in the opioid naive group, we achieved a pain score difference between BEMA Buprenorphine and placebo that approached statis
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
6. Derma Sciences Reports Second Quarter 2008 Results
7. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
8. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
9. Milestone Biosciences, LLC Further Strengthens Executive Management Team
10. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
11. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... presentation at the International Society for Cellular Therapy ... Achilles tendinosis currently in a Phase 1/2 clinical ... th from 5:30 PM to 7:00 PM ...
(Date:5/20/2015)... Wayland, MA (PRWEB) May 20, 2015 ... in history, especially for lawns. US Patented Pearl’s ... rescue for lawns around the country that are coming ... technology that addresses a number of major global concerns ... is the “non-grass” grass – the alternative to the ...
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., Inc. today ... Since the purchase of Tiger Industries and Tiger-Sunbelt ... H.J. Baker has leveraged the innovation of the Tiger-Sul ... of product offerings and solutions expertise. The deal brought ... of Tiger-Sul, transforming the company into a leading enterprise ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3
... 2 eResearchTechnology, Inc.,(eRT), (Nasdaq: ERES ... collection and interpretation services,announced today that Dr. ... Executive Officer, and Richard Baron, the Company,s ... the Deutsche Bank 33rd Annual,Healthcare Conference at ...
... ev3 Inc. (Nasdaq:,EVVV), a global endovascular device company, today ... and its revised financial,guidance for 2008., As previously ... quarter of 2008 representing a 65% increase over the ... over the fourth quarter of 2007. The,increase in net ...
... - QSV Biologics, Ltd (QSV), a North,American based ... awarded,a cGMP manufacturing contract for a recombinant protein ... manufactured at QSV,s Edmonton facility,and is intended for ... begin,immediately, and will include technology transfer, scale-up and ...
Cached Biology Technology:eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 3ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 4ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 5ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 6ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 7ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 8ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 9ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 10ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 11ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 12QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc. 2
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... 2008) As 17 countries and 30 organizations ... three major environmental groups World Wildlife Fund, ... on governments, businesses, scientists, non-governmental organizations and individuals ... protect coral reefs. The International Year of the ...
... search, researchers have discovered that the pancreas does indeed ... insulin-producing beta cells. If the finding made in adult ... represent an obvious target for therapeutic regeneration of beta ... 25 issue of Cell, a publication of Cell Press. ...
... New York University researchers have identified a weakness in ... exploited to produce new antibiotics. The researchers found ... Bacillus anthracis,s defense against the immune response launched by ... produce NO succumb to the immune system,s attack. ...
Cached Biology News:Environmental groups call for increased protection of coral reefs 2Elusive pancreatic stem cells found in adult mice 2Team IDs weakness in anthrax bacteria 2
... Perfuse cells right in your ... The Petri dish Perfusion Chamber has ... outflow that dampen the fluctuations of ... compartment and prevent bubbles from entering ...
... (BTI-TN-5B1-4) derived from Trichoplusia ni egg ... be capable of expressing significantly higher ... to other insect cells. High Five ... time as adherent cultures- Quick adaptation into ...
... assay system offers the following ... for batch-processing systems, Long lasting ... microplates such as 384-well and ... storage conditions ( 2 - ...
... kit consists of universal lysis buffer, PCR ... for 100 25 l volume PCR reactions. ... Gram negative or positive rod and coccus ... Bacillus Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and ...
Biology Products: